Savolitinib Induces Encouraging Efficacy, Safety in MET-Driven Papillary Renal Cell Carcinoma

A phase III study presented the 2020 ASCO Virtual Scientific Program showed encouraging efficacy data suggesting savolitinib could be used to treat patients with MET-driven papillary renal cell carcinoma.

Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news